Summarized by Masters of Longevity from PR Newswire.
FDA approved Skyrizi SC induction for adults with moderately to severely active Crohn’s disease.
Key Takeaways
- Phase 3 AFFIRM data are reported to support Skyrizi approval.
- Lutikizumab was found to meet the primary and most secondary endpoints.
- Regulatory submissions and presentations are planned into 2027.
